Compare Medpace Holdings Inc (MEDP) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Uranium Energy Corp — how do they compare? Medpace Holdings Inc trades at $597.39 (market cap $16.90B), while Uranium Energy Corp trades at $11.39 (market cap $5.67B). The key difference: Medpace Holdings Inc is far larger — about 3× Uranium Energy Corp's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Uranium Energy Corp nearer its low. Which is the better fit depends on your goals.
| MEDP | UEC | |
|---|---|---|
Market Cap | $16.90B | $5.67B |
Sector | Technology | Energy |
52-Week High | $620.59 | $20.14 |
52-Week Low | $393.42 | $9.04 |
Enterprise Value | $16.52B | $5.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
UEC trades at $11.36, down 0.18% on the day, with a bullish technical signal driven by moving averages despite a neutral oscillator reading. The company reported a net loss of $87.66 million in 2025, with revenue of $66.84 million, and faces significant profitability challenges with a negative net income margin of -513.24%. Recent news highlights insider selling and optimistic long-term uranium market forecasts.
Outlook hinges on uranium price recovery and production ramp-up, but risks include persistent losses, high valuation multiples, and execution delays. Analyst consensus is strongly bullish with 87.5% buy ratings, though fundamentals warrant caution due to cash burn and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
